EDIT Margin dodolan resik Editas

Editas Medicine Inc - logo grafis emiten EDIT

Editas Medicine, Inc. (EDIT) combines an elite team of geneticists with cutting-edge R&D to create CRISPR therapies that correct hereditary pathologies at the DNA level. The net profit margin reflects the business's efficiency dynamics, where -145.00 serves as the current metric level. The implementation of automated laboratories is currently accelerating the development of gene products, optimizing the path of innovation to market.

Rentabilitas dodolan resik Editas Corp (EDIT): kanggo periode 04.07.2022 - 20.11.2026

Editas (EDIT) - rincian metrik lan laporan keuangan

- rega saham lan prakiraan rega para ahli:
Analisis kabeh metrik perusahaan:Editas Medicine, Inc.
Produk dadi Editas Medicine Inc

Assessing the investment reliability of an asset requires an objective profitability analysis to avoid overpaying for temporary spikes in earnings. The net income-to-revenue ratio determines the efficiency of each unit of income, which for Editas Medicine, Inc. (EDIT) reflects the cost of maintaining a highly qualified staff of biologists; consequently, the net profit margin demonstrates the company's ability to convert scientific patents into financial stability.

Pesaing wigati

TEM: Margin dodolan resik|Tingkat bathi miturut bathi resik Qiagen QGEN|IONS (Isis Pharmaceuticals) - Margin dodolan resik|Repligen Inc. - Margin bathi resik|Margin dodolan resik RNA|CRSP - Margin resik|GeneDx - Rentabilitas dodolan miturut bathi resik|Tingkat bathi resik RARE|Beam Tx - Margin dodolan resik|SRPT - Margin dodolan resik|TWST (Twist Bio) - Rentabilitas dodolan miturut bathi resik|Rentabilitas dodolan resik TXG|Rentabilitas dodolan miturut bathi resik NTLA|Stoke Therapeutics Inc (STOK) - Margin dodolan perusahaan|Margin dodolan resik BLFS|Margin resik WVE (Wave Life Sciences Corp)|Margin resik Maze Therapeutics MAZE|Tingkat bathi resik SION|PRME - Margin resik|Margin dodolan perusahaan Taysha TSHA|QURE: Margin dodolan resik|Rentabilitas dodolan miturut bathi resik MeiraGTx PLC|RGNX (REGENXBIO Inc) - Margin dodolan resik|solidbio.com (SLDB) - Margin dodolan perusahaan|Margin resik Ocugen Corp (OCGN)|Pacific Biosciences of California, Inc. - Rentabilitas dodolan resik|Benitec Biopharma - Rentabilitas dodolan miturut bathi resik|DSGN: Rentabilitas dodolan resik|RCKT: Rentabilitas dodolan miturut bathi resik|FDMT - Margin dodolan resik|LXEO: Margin dodolan resik|Korro Bio Inc. - Tingkat bathi resik|Margin resik Silence Therapeutics Inc.|Rentabilitas dodolan resik PRQR (proqr.com)|Margin resik Codexis Bio (CDXS)|Margin dodolan resik sangamo.com (SGMO)|Margin resik nautilus.bio NAUT|Margin dodolan perusahaan Metagenomi, Inc (MGX)|Precision BioSciences Inc. - Margin dodolan resik|GBIO - Margin dodolan resik|BOLD: Margin dodolan resik|Rentabilitas dodolan resik XCUR|Margin resik Imunon|Phio Pharmaceuticals - Margin bathi resik|Margin resik Mustang Bio, Inc. (MBIO)|Margin dodolan perusahaan TransCode Therapeutics, Inc.|Margin resik Bionano Genomics BNGO|Tingkat bathi resik APDN|BLUE - Margin resik|Margin bathi resik IPA|Omega Therapeutics, Inc. (OMGA) - Margin resik|Singular Genomics Corp (OMIC) - Margin dodolan resik|RGLS (Regulus Therapeutics, Inc.) - Margin dodolan resik|SYRS: Tingkat bathi resik|Rentabilitas dodolan miturut bathi resik TBIO (Telesis Bio Inc.)|Margin dodolan resik TRACON Pharmaceuticals Inc. (TCON)|Margin resik Unity Bio UBX